CompletedPhase 4

Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases

United States12 participantsStarted 2018-08-03

Plain-language summary

This phase IV trial studies how well delaying positron emission tomography (PET)/magnetic resonance imaging (MRI) scan after injection of fluorodeoxyglucose (FDG) can improve the imaging of patients with cancer that has spread to brain (brain metastases). FDG is a type of imaging agent that doctors use to help "see" the images on a scan more clearly. Delaying PET/MRI scan after injecting FDG may improve how well doctors can tell the difference between healthy and unhealthy tissue.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pre-treatment adult patients with any solid organ metastasis and at least three intraaxial brain metastases including at least one enhancing \> 10 mm lesion * Rim or solid enhancing lesion(s) WITH a history of non-central nervous system (CNS) pathologic proven metastatic disease will be considered as a consensus between the referring radiation oncologist or neurosurgeon and a neuroradiology * Planned surgery or radiation to the metastases * Ability to undergo PET magnetic resonance (MR) examination Exclusion Criteria: * Known allergy to FDG or gadolinium based contrast agents * History of impaired renal function (glomerular filtration rate \[GFR\] \< 30) * Pregnant women are excluded

What they're measuring

assess the optimal fludeoxyglucose F-18 (fluorodeoxyglucose) positron emission tomography (FDG PET) imaging time post radiotracer administration that maximizes separation of activity between lesion and non-lesional parenchyma

Timeframe: through study completion, an average of a year

Trial details

NCT IDNCT05054998

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-04-26